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ABSTRACT  
The bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase-4 (PFKFB4) controls metabolic flux through allosteric 
regulation of glycolysis. Here we show that p53 regulates the expression of 
PFKFB4 and that p53-deficient cancer cells are highly dependent on the 
function of this enzyme. We found that p53 down-regulates PFKFB4 
expression by binding to its promoter and mediating transcriptional repression 
via histone deacetylases. Depletion of PFKFB4 from p53 deficient cancer 
cells increased levels of the allosteric regulator fructose 2,6-bisphophate, 
leading to increased glycolytic activity but decreased routing of metabolites 
through the oxidative arm of the pentose phosphate pathway. PFKFB4 was 
also required to support the synthesis and regeneration of nicotinamide 
adenine dinucleotide phosphate (NADPH) in p53 deficient cancer cells. 
Moreover, depletion of PFKFB4 attenuated cellular biosynthetic activity and 
resulted in the accumulation of reactive oxygen species and cell death in the 
absence of p53. Finally, silencing of PFKFB4 induced apoptosis in p53 
deficient cancer cells in vivo and interfered with tumour growth. These results 
demonstrate that PFKFB4 is essential to support anabolic metabolism in p53-
deficient cancer cells and suggest that inhibition of PFKFB4 could be an 
effective strategy for cancer treatment.   
 
 
Keywords: cancer metabolism; p53; PFKFB4; fructose 2,6-bisphosphate; 
NADPH; pentose phosphate pathway; tumour growth 
  
 3
 
INTRODUCTION 
Cancer cells need to generate large amounts of metabolic precursors to 
support macromolecule biosynthesis during cell growth and proliferation. 
Cancer cell metabolism is characterised by enhanced nutrient uptake and 
increased activity of many biosynthetic processes, including protein and lipid 
biosynthesis. Nicotinamide adenine dinucleotide phosphate (NADPH) is a 
cofactor for anabolic reactions and required for the regeneration of reduced 
glutathione (GSH) for the detoxification of reactive oxygen species (ROS). 
The enhanced demand for biosynthetic processes and control of oxidative 
stress makes NADPH synthesis and regeneration an essential process in 
cancer 26.  
The tumour suppressor p53 counteracts many of the metabolic alterations 
observed in cancer cells 21. Indeed, modulation of metabolic activity was 
shown to be a major component of the tumour suppressor activity of p53 25. 
Loss of p53 function leads to enhanced glucose uptake 19 but decreased 
mitochondrial oxidative metabolism 29. Activation of p53 by DNA damage 
induces the expression of TIGAR, a fructose-2,6-bisphosphatase domain 
containing protein, which reduces glycolytic activity and increases the flux of 
metabolites to the oxidative pentose phosphate pathway (PPP) 2 to facilitate 
nucleotide synthesis for DNA repair. Seemingly contradictory to this, loss of 
p53 in cancer cells enhances oxidative PPP activity by increasing the activity 
of glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate 
dehydrogenase (6PGD), the two NADPH-generating enzymes of this pathway 
12, 17. p53 also regulates the expression of malic enzymes 1 and 2 (ME1, 
ME2), two additional NADPH producing metabolic enzymes 18. It can 
therefore be concluded that deletion of p53 overall increases the synthesis 
and regeneration of NADPH to support biosynthetic processes in cancer cells.  
We have previously shown that 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase-4 (PFKFB4) supports the survival of prostate cancer cells in 
vitro and in vivo by reducing the generation of the allosteric regulator fructose 
2,6-bisphosphate (Fru-2,6-BP), thereby inhibiting glycolytic flux and promoting 
the production of NADPH for lipid synthesis and regeneration of GSH 35. 
Silencing of PFKFB4 blocked acetate-dependent lipid synthesis and resulted 
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in the accumulation of ROS in cancer cells 35. However, it was not known 
whether loss of p53 function alters the dependency of cancer cells on 
allosteric regulation of glycolysis by PFKFB4, thereby postulating a potential 
biomarker for therapeutic targeting strategies.  
We now demonstrate that p53 negatively regulates PFKFB4 expression by 
directly binding to the promoter of the gene. Conversely, loss of p53 function 
either by deletion of mutation increases the expression of PFKFB4 in cancer 
cells. Cancer cells that have lost p53 function are also highly sensitive to 
PFKFB4 depletion. Allosteric regulation of glycolysis by PFKFB4 is required 
for the routing of metabolites to the oxidative PPP to maintain NADPH 
synthesis and regeneration. Depletion of PFKFB4 in p53 deficient cancer cells 
increases oxidative stress and results in the induction of apoptosis. This 
dependence was also observed in xenograft tumours, where silencing of 
PFKFB4 caused more efficient blockade of tumour growth of p53 negative 
cancer cells. Our results reveal that inhibition of PFKFB4 interacts in a 
synthetic lethal manner with loss of function of p53 in cancer cells and provide 
a rationale for targeting allosteric regulation of glycolysis for pharmaceutical 
intervention in cancers that are defective in TP53.  
 
 
RESULTS 
p53 negatively regulates PFKFB4 expression 
To investigate whether PFKFB4 is regulated by p53, we analysed expression 
of the four human PFKFB isoforms in isogenic p53+/+ and p53-/- HCT116 colon 
cancer cells. mRNA levels of PFKFB4, but not any of the other PFKFB 
isoforms, were markedly increased in p53-/- cells compared to their wild type 
counterparts (Fig. 1a). This induction was similar to the increased expression 
of malic enzyme 1 (ME1) and malic enzyme 2 (ME2), which were previously 
identified as negative targets of p53 18, while expression of TIGAR was not 
altered between p53+/+ and p53-/- cells (Fig. 1b). In agreement with altered 
mRNA levels, we also detected increased expression of PFKFB4 protein in 
HCT116 p53-/- cells (Fig. 1c), while the other PFKFB isoforms showed no 
differential expression (Fig. S1a). Moreover, CRE-mediated deletion of p53 in 
primary embryonic fibroblasts (MEF) derived from tpr53fl/fl mice also resulted 
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in increased Pfkfb4 expression (Fig. 1d). Silencing of TP53 in HCT116 p53+/+ 
cells, using a lentiviral vector for the doxycycline-inducible expression of short 
hairpin RNA (shRNA) targeting p53, efficiently reduced the expression of p53 
and p21 but increased expression of PFKFB4 and ME2 (Fig. 1e). Conversely, 
expression of p53 in the p53 deficient ovarian cancer cell line SKOV3 caused 
a marked decrease in the expression of PFKFB4 mRNA and protein (Fig. 1f 
and g). 
 
The normally short-lived p53 protein is stabilized in response to DNA-damage 
23. We therefore treated p53+/+ and p53-/- HCT116 cells with the genotoxic 
agent etoposide and monitored changes in expression of p53 target genes. 
Etoposide caused a dose-dependent induction in p21 expression only in 
p53+/+ but not in p53-/- cells (Figure 2a and S1b, left graphs). In the same 
cells, expression of PFKFB4 was reduced in response to etoposide treatment 
only in the presence of p53+/+ (Fig. 2a and S1b, middle graphs). This was 
similar to the regulation of ME2 (Fig. 2a and S1b, right graphs). Similar results 
were also obtained in a second p53 wild type colon cancer cell line, LOVO 
(Fig. 2b), and a p53 wild type breast cancer cell line, MCF7 (Fig. 2c). 
 
Analysis of the human PFKFB4 promoter revealed several putative p53-
response elements. Chromatin immunoprecipitation (ChIP) experiments 
showed specific binding of p53 to two of these sites (Fig. 2d), confirming that 
p53 regulates PFKFB4 expression by binding to its promoter. Negative 
regulation of transcription by p53 frequently involves the recruitment of 
histone deacetylases (HDACs) to the promoter regions of target genes 13, 31. 
We therefore investigated whether inhibition of HDACs by trichostatin A (TSA) 
prevents the negative effect of p53 on PFKFB4 expression. TSA treatment 
efficiently blocked PFKFB4 downregulation in the presence of etoposide in 
HCT116 p53+/+ and LOVO colon cancer cells, as well as in MCF7 breast 
cancer cells (Fig. 2e).  
 
Taken together, these results demonstrate that p53 negatively regulates 
expression of PFKFB4, both at basal levels and when p53 is activated in 
response to DNA damage. To confirm the link between PFKFB4 expression 
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and p53 also in human cancer, we interrogated public datasets from the Gene 
Expression Omnibus (GEO). We retrieved expression data of cancer samples 
with differential p53 status from a study investigating somatic mutations in 
lung adenocarcinoma 8. Comparative analysis revealed that PFKFB4 
expression is significantly increased in p53-/- lung adenocarcinomas when 
compared to p53+/+ tissues of the same cancer type (Fig. S1c).  
 
 
PFKFB4 is essential for the viability of p53 null cancer cells 
PFKFB proteins are homodimeric bifunctional enzymes that control the rate of 
glycolysis by modulating levels of Fru-2,6-BP, an allosteric activator of 
phosphofructokinase 1 (PFK1) and inhibitor of fructose-1,6-bisphosphatase 
(FBPase-1) 32. Allosteric regulation by PFKFB4 regulates the distribution of 
metabolites between glycolysis and the oxidative PPP and is required for the 
generation of NADPH for anabolic reactions and anti-oxidant synthesis in 
cancer cells 35,39.  
 
To investigate whether the increased expression of PFKFB4 is linked to the 
altered metabolic demand of p53-/- cancer cells, we performed silencing 
experiments using inducible expression of shRNAs targeting 
PFKFB4. Depletion of PFKFB4 using two independent shRNA hairpins only 
slightly reduced the cell number in p53+/+ cells. In contrast, depletion of 
PFKFB4 caused a substantial reduction of viability in p53í/í cells (Fig. 3a). 
Efficient depletion of PFKFB4 was confirmed in both HCT116 p53+/+ and p53-/- 
cell lines, with sequence #68 achieving an 80% reduction in mRNA while 
expression of sequence #64 resulted in a 50% reduction (Fig. 3b). We also 
controlled that depletion of PFKFB4 did not cause any changes in the 
expression of PFKFB1, PFKFB2 or PFKFB3 (Fig. S2a). Furthermore, to 
establish specificity of silencing, we generated shRNA-insensitive expression 
constructs by introducing silent mutations within the PFKFB4 coding 
sequence. These constructs were expressed in p53+/+ and p53-/- HCT116 
colon cancer cells, which were subsequently infected with the lentiviral shRNA 
expression constructs targeting endogenous PFKFB4. We confirmed that the 
expression of exogenous PFKFB4 mRNA was not changed upon doxycycline 
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treatment (Fig. S2b and c). Importantly, reduced viability of HCT116 p53-/- 
cells in response to shRNA induction was completely rescued by re-
expression of PFKFB4 (Fig. 3c).  
 
We next investigated the wider applicability of these findings using a panel of 
colon cancer cell lines. These included three additional p53 wild type colon 
cancer cell lines (RKO, LOVO and LS174T) and two colon cancer cell lines 
(SW680 and SW620) expressing a mutant form of p53 carrying a mutation 
within the DNA binding domain (R273H). This mutant exerts a dominant 
negative effect by blocking DNA binding of the wild type protein 43. Wild type 
cell lines expressed significantly lower levels of PFKFB4, with RKO cells 
expressing nearly undetectable levels (Fig. 3d and e). We next transduced 
two p53 wild type and p53 mutant cell lines with lentiviral shRNA constructs 
targeting PFKFB4. Depletion of PFKFB4 reduced the viability of both p53 
mutant cell lines, while not affecting viability of cells expressing wild type p53 
(Fig. 3e and f). Conclusively, these results confirm that PFKFB4 is selectively 
required for the viability of p53 deficient cancer cells. 
 
 
PFKFB4 maintains balance of metabolite flux between glycolysis and 
pentose phosphate pathway in p53 deficient cancer cells 
We next asked which catalytic activity of PFKFB4 mediates the survival of 
p53-/- cells. We first established the efficiency and timing of PFKFB4 protein 
depletion in response to shRNA expression. While mRNA levels were already 
efficiently reduced after 2 days of doxycycline treatment in cells expressing 
sequence #68, substantial amounts of protein were still detectable after 3 
days of shRNA induction (Fig. S3a and b). Moreover, p53 deficient cells 
showed a larger increase in PFKFB4 protein expression at the later time point 
(Fig. 4a and S3d). We next determined the levels of Fru-2,6-BP, the substrate 
of the fructose-2,6-bisphosphatase activity of PFKFB4 at 3 and 6 days after 
PFKFB4 depletion in both cell types. At the earlier time point, depletion of 
PFKFB4 caused an increase in Fru-2,6-BP in both p53+/+ and p53í/í cells (Fig. 
S3c). However, at the later time point, where p53í/í cells show increased 
expression of the protein, no changes in metabolite levels were observed in 
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p53+/+ cells. In contrast, depletion of PFKFB4 for 6 days caused a significant 
increase in Fru-2,6-BP levels in p53 deficient cells (Fig. 4b). Induction of the 
second, less effective, shRNA sequence only caused partial ablation of 
PFKFB4 protein after 6 days, which also increased the levels of Fru-2,6-BP 
only in p53í/í cells, although the data failed to reach statistical significance 
(Fig. S3e). 
 
To further investigate the consequences of PFKFB4 depletion on cellular 
metabolism, we examined changes in glucose uptake using 2-[N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG), a fluorescent 
derivative of 2-deoxyglucose. p53 inhibits glucose uptake by downregulating 
the expression of glucose transporters GLUT1 and GLUT4 38. Moreover, 
activation of p53 suppresses NF-κB activation and reduces glucose uptake 
and glycolysis by blocking the expression of GLUT3 19. However, we 
observed no major differences in 2-NBDG uptake between p53+/+ and p53-/- 
cells. Depletion of PFKFB4 caused a moderate increase in 2-NBDG uptake in 
both cell lines, which was significant only in p53-/- cells (Fig. S3f).  
 
To provide further detail of the metabolic response to PFKFB4 depletion, we 
also performed mass isotopomer distribution (MID) analysis after exposing 
cells to [1,2-13C]-glucose that allows us to estimate the relative contribution of 
the PPP to the metabolite pool in glycolysis. Specifically, molecules with one 
13C atom (M+1) indicate that they transited through the oxidative PPP, 
whereas molecules with two 13C atoms (M+2) came directly from glycolysis 
(Fig. S3g). We analysed the mass isotopomer fractions of fructose-
bisphosphate (FBP) and phosphoenolpyruvate (PEP), and found that 
silencing of PFKFB4 in p53-/- HCT116 cells leads to an increased fraction of 
M+1 over the M+2 fraction for both FBP and PEP (Fig. S3h), that means a 
relative increase in the fraction of pentose phosphates that is routed back to 
glycolysis through the non-oxidative PPP. The most plausible explanation for 
this result is that PFKFB4 depletion causes a difference in the outflow of 
pentose-phosphate for purine biosynthesis, which is the major biosynthetic 
sink for PPP intermediates. Hence, depletion of PFKFB4 from p53-/- cells 
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induces a reduction in the net flux through the oxidative PPP from glucose-6-
phosphate to the pentose-phosphate pool, but the latter is seemingly 
channelled back because of a reduced outflow to purine synthesis. 
 
MID analysis is not able to provide any estimation of the rate at which 
metabolites pass through a metabolic pathway. We next investigated the 
effect of PFKFB4 depletion on glycolytic flux (ECAR) and oxygen 
consumption (ORC) using the Seahorse Bioanalyzer. Both cell lines showed 
similar ECAR/OCR ratios in the basal state and depletion of PFKFB4 had only 
a minor effect in p53+/+ cancer cells (Fig. 4c). In contrast, p53í/í cells showed 
a strong increase in the ECAR/OCR ratio upon PFKFB4 depletion (Fig. 4c). 
This was caused by an increase in glycolysis and a decrease in respiration 
(Fig. 4d), confirming that PFKFB4 is required to limit glycolytic flux in these 
cells.  
 
Increased glycolysis affects metabolite flux towards the oxidative and non-
oxidative arm of the PPP. We therefore analysed the activity of the oxidative 
PPP by comparing the production of 14CO2 from 1-14C-glucose relative to that 
from 6-14C-glucose. We observed a significant reduction of this ratio in 
HCT116 p53-/- cells after silencing of PFKFB4 (Fig. 4e). In contrast, silencing 
of PFKFB4 had no effect on PPP flux in p53+/+ cells Fig. 4e). This confirms 
that PFKFB4 is required to maintain the activity of the oxidative arm of the 
PPP in p53 deficient cancer cells. 
 
 
PFKFB4 maintains NADPH production for biosynthetic activity and 
antioxidant production 
The metabolic outputs of the PPP include the synthesis of riboses for 
nucleotide biosynthesis and the regeneration of NADPH. We therefore 
investigated whether PFKFB4 influences NADPH levels and oxidation status 
in cancer cells. Interestingly, we found that levels of NADPH as well as the 
total amount of this coenzyme (NADPH+NADP+) where reduced following 
PFKFB4 silencing only in p53-/- cells (Fig. 5a, left graph). In contrast, the ratio 
between the reduced and oxidised forms of the coenzyme was not altered 
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(Fig. 5a, right graph). Moderate depletion of PFKFB4 protein achieved by the 
second, less efficient sequence also reduced NADPH levels (Fig. S4a). This 
effect was only detectable at the later time point, when efficient depletion of 
PFKFB4 protein was achieved (Fig. S4a), while short-term silencing had no 
effect (Fig. S4b). We additionally determined expression of ME1 and ME2 
after PFKFB4 knockdown and observed no compensation by these genes 
(Fig. S4c). In agreement with the results of the MID analysis, this result 
suggests that PFKFB4 is required to maintain NADPH regeneration through 
the oxidative arm of the PPP and also facilitates the synthesis of the 
coenzyme by providing riboses via the biosynthetic output of this pathway.  
 
NADPH provides reducing power for biosynthetic reactions, including lipid 
biosynthesis, leading us to investigate whether inhibition of PFKFB4 affects 
the activity of this process in cancer cells. We first established that p53-/- cells 
display a higher rate of acetate-dependent lipid biosynthesis compared to 
p53+/+ cells (Fig. 5b). Moreover, p53 deficient cells also showed increased 
activity of a reporter containing a fragment of the human HMG-CoA synthase 
promoter carrying an intact sterol regulatory element (SRE) (Fig. 5c). This 
activity depends on the sterol regulatory element binding proteins (SREBP), a 
family of transcription factors controlling genes involved in fatty acid and 
cholesterol biosynthesis 1. This is in agreement with previous reports showing 
that SREBP is activated by loss or mutation of p53 10, 44. It is therefore 
possible that p53 deficient cancer cells have a higher demand for NADPH 
than their p53 proficient counterparts, which is aided by the induction of 
PFKFB4. In agreement with this hypothesis, silencing of PFKFB4 caused a 
stronger reduction in acetate-dependent lipid synthesis in p53-/- cells 
compared to p53+/+ cells (Fig. 5d).  
 
Increased NADPH demand also compromises the availability of this 
coenzyme for the production of antioxidants, leading to oxidative damage and 
ROS generation. We therefore investigated the effect of PFKFB4 depletion on 
cellular ROS levels in the two cell lines. While silencing of PFKFB4 had no 
effect on ROS in p53+/+ cells, it caused a strong increase in ROS levels in 
p53í/í cells (Fig. 5e). Furthermore, treatment with the antioxidant N-
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acetylcysteine (NAC) blocked the induction of apoptosis in response to 
PFKFB4 depletion in p53-/- cells (Fig. 5f), indicating that ROS accumulation is 
the cause of the reduced viability observed in these cells.  
 
Taken together, these results confirm the role of PFKFB4 in promoting the 
routing of metabolites from glycolysis into the PPP for the synthesis and 
regeneration of NADPH to support anabolic reactions and maintain cellular 
redox balance. This function is essential to fulfil the increased NADPH 
demand of p53 deficient cancer cells to drive biosynthetic processes including 
lipid synthesis (Fig. 5g). 
 
 
PFKFB4 silencing inhibits spheroid and tumour growth in the absence 
of p53  
Metabolic reprogramming in cancer supports cell growth under oxygen and 
nutrient limited conditions, such as those found in hypo-vascularised tumour 
regions 7, 30. The environmental conditions found in tumours can generate 
specific metabolic constraints and reveal sensitivities of cancer cells that 
could be exploited for therapy.  
To investigate the contribution of PFKFB4 to the viability of p53 deficient 
cancer cells under nutrient limited conditions, we employed tumour spheroid 
culture conditions. These multi-layered 3-dimensional structures recreate 
nutrient and oxygen gradients found in live tumours 5. Silencing of PFKFB4 
induced a reduction in spheroid volume in both p53+/+ and p53-/- HCT116 
colon cancer cells (Fig. S5a), indicating that the metabolically compromised 
conditions present in this culture system could sensitise p53+/+ cells towards 
PFKFB4 inhibition. However, depletion of PFKFB4 caused a further reduction 
in spheroid growth in p53-/- cells, confirming the increased dependency of the 
cells on this enzyme in the absence of the tumour suppressor.  
 
We next investigated the importance of PFKFB4 for tumour growth using a 
xenograft tumour model. For this, we first generated p53+/+ and 
p53í/í HCT116 cells expressing luciferase and used these for expression of 
inducible shRNA-constructs targeting PFKFB4 or scrambled shRNA controls. 
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Efficient PFKFB4 silencing and inhibition of cell proliferation was confirmed in 
these cells (Fig. S5b and c). Cells were then injected subcutaneously into 
nude mice and tumour growth was followed over time in control and 
doxycycline treated cohorts. As control, we established that PFKFB4 silencing 
had no effect on the size of tumours generated by HCT116 cells expressing a 
scrambled shRNA control (Fig. S5d and e).  
 
Interestingly, we found that PFKFB4 mRNA levels were higher in p53-/- 
tumours, confirming that the differential expression of this gene is also 
maintained in vivo, and that doxycycline treatment efficiently depleted 
PFKFB4 mRNA from both types of tumours (Fig. S5f). Strong silencing of 
PFKFB4 by sequence #68 slowed the growth of p53+/+ tumours, with a 
plateau being reached after 15 days of doxycycline treatment. Induction of the 
less efficient sequence (#64) did not impair growth of p53+/+ tumours (Fig. 6a, 
left graphs). In contrast, expression of either shRNA sequences efficiently 
blocked tumour growth in the p53í/í background. Indeed, strong silencing by 
sequence #68 caused a reduction of the initial tumour mass and a 17-fold 
reduction of tumour size compared to untreated controls at the end of the 
experiment (Fig. 6a, right graphs). Consequently, the effects of PFKFB4 
depletion on bioluminescence detection (Fig. 6b), tumour weight (Fig. S5d) 
and tumour size (Fig. S5e) were more pronounced in p53í/í background.  
 
Histological analysis showed that tumour regression was accompanied by the 
appearance of apoptotic areas (Fig. 6c), while minor changes in proliferation 
were detected (Fig. 6d and S5g). We also analysed transcriptional changes 
associated with PFKFB4 inhibition in these tumours using whole genome 
RNA sequencing (RNAseq). Interestingly, both p53+/+ and p53í/í tumours 
showed downregulation of genes associated with ribosome synthesis, 
assembly of the ternary translation complex and rapamycin sensitivity (Fig. 6e 
and S6a). However, only p53í/í tumours showed regulation of genes linked to 
apoptosis and oxidative stress (Fig S6a). Finally, analysis of public gene 
expression data revealed that high expression of the glycolytic enzyme 
PFKFB4 is a predictor of reduced survival in breast and non-small cell lung 
cancer patients (Fig. S6b and c).  
 13
In conclusion, our study demonstrates that p53 represses PFKFB4 
expression, and that allosteric regulation of glycolytic flux by PFKFB4 
supports lipid synthesis and prevents oxidative stress in p53 deficient cancer 
cells to support cell proliferation and tumour growth.  
 
 
DISCUSSION 
Loss of p53 in cancer cells inactivates important DNA-damage and cell cycle 
checkpoints but has also multiple effects on cellular metabolism 27. Indeed, 
the metabolic effects of p53 may be sufficient to explain its functions as a 
tumour suppressor 25. In normal cells, p53 regulates metabolism on multiple 
levels 21. For example, p53 reduces glucose uptake by lowering NF-κB 
dependent expression of GLUT3 19. Induction of p53 in response to DNA 
damage inhibits glycolysis through the induction of TIGAR 2. It also reduces 
the expression of several glycolytic enzymes via a microRNA-dependent 
mechanism 20 and increases mitochondrial activity by inducing the expression 
of cytochrome c oxidase 2 (SCO2) 29. At the same time, p53 also increases 
the ability of cells to respond to nutrient starvation, by facilitating cell cycle 
arrest, autophagy or the use of alternative energy source, such as lipids 21. 
Cancer cells deficient in p53 can therefore be more sensitive towards 
perturbations within the metabolic network and these selective vulnerabilities 
can be exploited for cancer therapy 28. 
 
Enhanced macromolecule biosynthesis increases the cellular demand for 
NADPH, the reducing coenzyme for anabolic reaction. Cancer cells therefore 
need to upregulate mechanisms that increase NADPH synthesis and 
regeneration to maintain rapid proliferation and prevent excess oxidative 
stress. We demonstrate that p53 negatively regulates expression of PFKFB4, 
while loss of p53 increases the expression of PFKFB4, an enzyme that 
controls cellular levels of the allosteric regulator Fru-2,6-BP. Through this 
regulation, p53 alters the routing of metabolites between glycolysis and the 
pentose phosphate pathway, which is critical for NADPH synthesis and 
regeneration. Depletion of PFKFB4 impairs the ability of cancer cells to 
 14
generate sufficient amounts of reducing cofactors to fulfil the demand 
generated by increased lipid synthesis. As a result, inhibition of PFKFB4 
selectively increases oxidative stress in p53 deficient cancer cells, leading to 
reduced viability in vitro and tumour regression in vivo.  
 
Several mechanisms have been proposed for the negative regulation of gene 
expression by p53. These include competition for DNA binding or 
transactivation function of positive regulators of transcription 34. We found that 
p53 directly binds to two p53-response elements within the PFKFB4 promoter. 
Moreover, we found that activation of p53 by DNA damaging agents reduced 
PFKFB4 expression, which was blocked by addition of TSA, suggesting that 
p53 represses transcription by recruiting HDACs. Loss of p53 relieves this 
inhibition and allows increased expression of PFKFB4.  
 
Allosteric regulation of glycolytic activity by PFKFB proteins is an important 
principle for the control of metabolic flux in cancer cells 36. PFKFB proteins 
have two independent catalytic centres and it is important to establish the 
exact role of PFKFB4 within the metabolic network of cancer cells. We have 
previously shown that PFKFB4 limits Fru-2,6-BP levels and induce the routing 
of metabolites into the PPP to support NADPH production and ROS 
detoxification in prostate cancer cells 35. In contrast, a recent study observed 
that PFKFB4 promotes the synthesis of Fru-2,6-BP to increase glycolytic flux 
in cancer cells grown under hypoxic conditions or as xenograft tumours 6. 
Here we show that depletion of PFKFB4 increases the levels of Fru-2,6-BP in 
p53 deficient colon cancer cells. Mass isotopomer distribution analysis 
confirmed that depletion of PFKFB4 increases the relative fraction of pentose-
phosphates that are routed back to glycolysis from the non-oxidative PPP. We 
also found that PFKFB4 depletion increases glycolytic rate and decreased 
activity of the oxidative arm of the PPP. Together, these metabolic changes 
results in reduced availability of PPP intermediates for biosynthetic processes, 
such as the production of NADPH, an essential cofactor for biosynthetic 
reaction. Indeed, NADPH levels were dramatically reduced following PFKFB4 
depletion. This resulted in the selective induction of oxidative stress and cell 
death in p53 deficient cancer cells.  
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There are several factors that contribute to the exquisite sensitivity of p53 
deficient cancer cells towards PFKFB4 depletion. One is the increased 
biosynthetic demand of p53 deficient cancer cells. p53 was shown to 
decrease the expression of lipogenic genes in adipocytes of obese mice 44. 
Loss of p53 increases the activity of mTORC1 9, which drives both protein and 
lipid biosynthesis 22. As lipid biosynthesis requires large amounts of NADPH, 
regulatory mechanisms that support the production of this coenzyme must be 
upregulated when lipid biosynthesis is high. Another explanation could be that 
p53 deficient cancer cells fail to undergo cell cycle arrest under metabolic 
starvation conditions, such as the absence of exogenous serine 28. It is 
therefore likely that p53 deficient cells are unable to adapt to the altered 
metabolite flux following PFKFB4 depletion by efficiently downregulating 
NADPH-consuming biosynthetic processes. This would cause further NADPH 
depletion, leading to oxidative stress and cell death. In line with this 
hypothesis, the reduction in tumour growth observed after strong PFKFB4 
depletion in p53 proficient cancers was not associated with the induction of 
cell death. Remarkably, p53 proficient cancer cells were not affected in their 
ability to form xenograft tumours when PFKFB4 was partially depleted using a 
less efficient shRNA sequence. In contrast, p53 deficient cancer cells were 
highly dependent on PFKFB4, as both partial and efficient silencing blocked 
tumour growth. Moreover, depletion of PFKFB4 from p53 deficient tumours 
resulted in the induction of apoptosis and tumour regression.  
 
Dynamic regulation of carbohydrate flux is essential to counteract oxidative 
stress in yeast 33. In cancer, the control of NADPH synthesis and regeneration 
to maintain anabolic metabolism and antioxidant production is an essential 
function of drivers of oncogenic transformation. The results of this study 
demonstrate that allosteric regulation of the glycolytic flux by PFKFB4 is 
essential for the survival of p53 deficient cancer cells. This synthetic lethality 
suggests that targeting PFKFB4 could be an effective strategy for the 
treatment of tumours that have lost the function of this important tumour 
suppressor. 
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MATERIALS AND METHODS   
Cell culture and reagents 
HCT116 p53+/+ and p53-/- 4 were a gift of B. Vogelstein (Johns Hopkins 
University, Baltimore). HEK 293T, MCF7, LOVO, LS174T, SW480 and 
SW620 cells were from LRI Cell Services. SKOV3, and also MCF7, LOVO 
were from CRUK-CI Biorepository Services. All cell lines were authenticated 
by STR profiling and used at low passage. All cell lines were confirmed to be 
free from mycoplasma throughout the experiments by regular testing. Cells 
were cultured at 37°C in a humidified incubator at 5% CO2 in Dulbecco's 
modified Eagle's medium (DMEM, Life Technologies) with 10% foetal bovine 
serum (FBS, Sigma) and 2mM L-glutamine. Primary MEF were derived from 
embryonic day 12.5 (E12.5) embryos and were cultured in DMEM 
supplemented with 10% FBS at 37°C with 5% CO2 and 3% O2. For Cre-
mediated deletion of p53 floxed alleles, MEF from tp53fl/fl mice were infected 
with Adeno-Cre-green fluorescent protein (GFP) or Adeno-GFP virus (Gene 
Transfer Vector Core, Iowa University) for 48 hr. Virus was removed and the 
cells were allowed 48 hr to recover before passaging.  
Antibodies for PFKFB1 (SAB1408617) and PFKFB2 (SAB1406248) were from 
Sigma, for PFKFB3 (H00005209-A01) from Abnova and PFKFB4 (ab137785) 
from Abcam or from Abgent (Center, AP815c). Antibodies for p53 (DO-1, sc-
126 x) were from Santa Cruz Biology. All other reagents were from Sigma. 
The HMGCS promoter constructs pGL3-SYNwt-luc and pGL3-SYNmutSRE1 
were a gift from J. Swinnen (Catholic University, Leuven).  
 
RNA extraction, reverse transcription and RT-qPCR 
Total RNA was isolated using an RNeasy kit (Qiagen). 2µg of total RNA was 
used for first strand cDNA synthesis with SuperScript II Reverse 
Transcriptase and oligo-dT primers (Invitrogen). Real time PCR was 
performed with SYBR® Green PCR Master Mix (Applied Biosystems) using 
Quantitect primers (Qiagen) in an ABI PRISM 7900 Sequence Detection 
System (Applied Biosystems). The relative amount of all mRNAs was 
calculated using the comparative CT method after normalization to B2M 
and/or Bactin. 
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Protein analysis 
Cells were lysed in Triton lysis buffer (1% Triton X100, 50mM Tris pH7.5, 
300mM NaCl, 1mM EGTA, 1mM DTT, 1mM NaVO4, Protease-Inhibitor-
Cocktail and Phosphatase-Inhibitor-Cocktail (Roche)). Proteins were 
separated on SDS-PAGE and blotted onto PVDF membrane (Immobilon). 
Membranes were blocked with 3% BSA, incubated with antibody solutions 
and signals were detected using ECL-reagent. 
 
Generation of doxycycline-inducible shRNA cell lines and expression of 
p53 in SKOV3 cells 
Lentiviral vectors containing short hairpin RNA sequences targeting PFKFB4 
were described previously 35. shRNA sequences targeting p53 were cloned 
into the TetOnPLKO lentiviral vector using the following oligonucleotides: 
forward 5’- 
CCGGCACCATCCACTACAACTACATCTCGAGATGTAGTTGTAGTGGATG
GTGTTTTT and reverse 5’- 
AATTAAAAACACCATCCACTACAACTACATCTCGAGATGTAGTTGTAGTG
GATGGTG. Lentiviruses were produced by co-transfecting HEK 293T with 
shRNA plasmids and the packaging plasmids pCMVǻR8.91 (gag-pol) and 
pMD.G (VSV-G glycoprotein) 45. Supernatants containing lentiviruses were 
collected 48h after transfection, mixed with polybrene (8ȝg/ml) and used for 
infection. Fresh medium containing puromycin (2ȝg/ml) was added after 24 
hours and cells were selected for at least 48 hours before use. 
The coding sequence of human TP53 was excised from pCMV-Neo-Bam p53 
wt (Addgene, 16434) and inserted into the lentiviral vector pBOBI (a gift from 
the Verma laboratory, Salk Institute, La Jolla to K. Brindle). In the resulting 
vector, mStrawberry is separated from TP53 by an E2A sequence (EF1-S-
p53_WT), which results in expression from a single mRNA transcript in 
equimolar concentrations. After lentiviral transduction, SKOV3 cells displaying 
similar levels of fluorescence were single cell sorted using a cell sorter BD 
FACSAria (Flow Cytometry, CRUK-CI), and a homogenous population was 
established.   
 
Chromatin immunoprecipitation (ChIP) assay 
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TP53 binding sites were predicted in the promoter of the human PFKFB4 
gene using the MatInspector tool from Genomatix. For ChIP assays, cells 
were washed with PBS and crosslinked with 1% formaldehyde for 15min at 
37°C. The reaction was stopped by the addition of glycine to 125mM final 
concentration. Samples were sonicated to generate DNA fragments with an 
average size below 1,000 base pairs, followed by immunoprecipitation with 
the indicated antibodies. Bound DNA fragments were eluted and amplified by 
PCR using the following primer pairs: PFKFB4_p53-site1 5’-
CGTCCACACTGCCTGGAAA-3’, 5’-CACAGCCCAACTCCATTGC-3’; 
PFKFB4_p53-site2 5’-TGAGCATGTGCGGAAGGA-3’, 5’-
AAAGGAACCCATGAGGGAAGTT-3’; p21_p53-site 5’-
CTGAAAACAGGCAGCCCAAG-3’, 5’-GTGGCTCTGATTGGCTTTCTG-3’ 
 
Cell Viability Assays 
Cells were seeded on 12-well plates. After incubation, cells were fixed with 
70% ethanol, stained with 0.01% crystal violet, washed and dried. For 
quantification, dye was extracted with 10% acetic acid and OD was measured 
at 560nm.  
 
Generation of PFKFB4 constructs 
The Hs_PFKFB4 cDNA was obtained from Origene and used as template for 
cloning into pBabe-blast using the BD In Fusion PCR Cloning kit (Clontech) 
and the following primers: (forward 5’- 
TCTAGGCGCCGGCCGATGGCGTCCCAACGG and reverse 5’-
CTGTGCTGGCGAATTTCACTGGTGAGCAGG). shRNA-insensitive 
constructs were generated by site-directed mutagenesis using the following 
primers: (PFKFB4ins68: forward 5’- 
GGCCAGTATCGCCGGGATGTCGTGAACACGTATAAATCTTTTG and 
reverse 5’- 
CAAAAGATTTATACGTGTTCACGACATCCCGGCGATACTGGCC; 
PFKFB4ins64: forward 5’-
CCTGAGGTCATAGCTGCGAATATAGTCCAGGTCAAACTGGGCAGCC and 
reverse 5’- 
GGCTGCCCAGTTTGACCTGGACTATATTCGCAGCTATGACCTCAGG).  
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Determination of Fru-2,6-BP  
Cells were homogenized in 50mM NaOH and 0.1% Triton X-100, heated to 
80°C for 5min, and centrifuged for 5min. The supernatant was neutralized 
with acetic acid in 20mM HEPES. Fru-2,6-BP was determined as previously 
described 42. Protein concentration was used for normalization. 
 
2-NBDG uptake 
Cells were treated with 1µg/ml doxycycline for 6 days, washed with PBS and 
incubated in media with 100µM of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) 
amino]-2-deoxy-D-glucose (2-NBDG, Sigma), a fluorescent derivative of 2-
doexyglucose, for 20min. Medium was removed and cells were washed twice 
in PBS followed by FACS analysis. DAPI was added prior to analysis to 
exclude dead cells. 
 
Analysis of cellular respiration 
Cells were treated with 1µg/ml doxycycline for 5 days. 4x105 cells were plated 
in sextuplets in a 96-well XF culture plate. 24 hours later, medium was 
changed to assay medium (Seahorse Biosciences) supplemented with 1mM 
sodium pyruvate and 10mM Glucose with pH adjusted to 7.4. Cells were 
incubated in a CO2-free atmosphere for 1 hour and oxygen consumption 
(OCR) and extracellular acidification (ECAR) rates were determined using a 
XF96 Extracellular Flux Analyser (Software Version 1.4, Seahorse 
Biosciences, North Billerica, USA). During the experiment, 1ȝM oligomycin A 
(Sigma), 0.4ȝM FCCP (Sigma) and 1ȝM antimycin A (Sigma) were injected. 
Rates were normalized to total protein content determined by sulforhodamine 
B staining. 
 
14C-glucose incorporation into CO2 
Cells were cultivated in the presence or absence of doxycycline for 6 days 
and then treated with 1µCi 1-14C or 6-14C glucose and incubated at 37°C for 
90min. To release 14CO2, 150µl perchloric acid was added to each well, 
immediately covered with phenylethylamine saturated paper and incubated at 
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room temperature for 24 h. The paper was then analysed by scintillation 
counting. 
 
Mass isotopomer distribution analysis 
Cells were labeled with 17.5mM 1,2-13C-glucose (Cambridge Isotope 
Laboratories) for 24h and extracted using acetonitrile/methanol/water 
(40/40/20). Dried cell extracts were resuspended in 100µL deionized water, 
10µL of which were injected into a Waters Acquity UPLC with a Waters T3 
column (150 x 2.1mm x 1.8µm; Waters Corporation, Milford, MA, USA) 
coupled to a Thermo TSQ Quantum Ultra triple quadrupole instrument 
(Thermo Fisher Scientific, Waltham, MA, USA) with electrospray ionization. 
Compound separation was achieved by a gradient of two mobile phases (i) 
10mM tributylamine, 15 mM acetic acid, 5% (v/v) methanol and (ii) 2-propanol 
3 and mass isotopomer distributions (MIDs) of intact and fragmented carbon 
backbones were acquired as described in 37 and correct for natural isotopic 
abundance. 
 
Determination of NADPH levels  
For detection of NADPH, cells were lysed in buffer containing 20mM 
nicotinamide, 20mM NaHCO3 and 100mM Na2CO3. Scraped cells were 
sonicated and 150ȝl cleared supernatants were incubated for 30min at 60°C. 
20µl of heated or not heated supernatant were then mixed with 160µl NADP-
cycling buffer (100mM Tris-Cl pH 8.0, 0.5mM thiazolyl blue, 2mM phenazine 
ethosulfate, 5mM EDTA and 1.3 IU glucose-6-phosphate dehydrogenase). 
After 1min incubation in the dark at 30°C, 1mM glucose-6-phosphate was 
added and the change in absorbance at 570nm was measured every 30 sec 
for 4min at 30°C. Protein concentration was used for normalization. 
 
Determination of acetate-dependent lipid synthesis  
Cells were incubated in medium containing 10µCi/ml [1-14C] acetate (85ȝM 
final concentration, Perkin Elmer) for 3 hours. After washing three times with 
PBS, cells were lysed in 0.5% Triton X-100/PBS. Lipids were extracted by 
successive addition of 2ml methanol, 2ml chloroform, and 1ml dH2O. Phases 
were separated by centrifugation before the organic phase was dried and 
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used for scintillation counting. Results were normalized to total protein content 
determined by sulforhodamine B staining. 
 
Reporter assays 
Cells were transfected with 0.5µg pGL3-SYNwt-luc or pGL3-SYNmutSRE1 41 
and 0.5ng phRL-SV40 using Lipofectamine™ 2000. Cells were lysed and 
activity was determined using a Dual Luciferase assay (Promega). 
 
Determination of ROS levels  
ROS levels were determined by incubating cells for 30min at 37ºC in medium 
with 1.6 µM CM-H2-DCFDA (Molecular Probes) followed by FACS analysis. 
DAPI was added prior to analysis to exclude dead cells. 
 
Apoptosis assay 
Cells were trypsinised and stained with Annexin V-pacific blue and propidium 
iodide. Apoptotic cells were determined by FACS analysis. 
 
Induction of spheroid growth 
For spheroid formation, cells were trypsinized, counted and placed in 96-well 
ultralow attachment plates (Costar). Spheroid formation was initiated by 
centrifugation at 650 x g for 10min and cultures were incubated for 13 days. 
Spheroid size was determined by imaging on an inverted microscope 
(Axiovert 100M, Carl Zeiss) and images were processed in ImageJ.  
 
Xenograft experiments 
To generate luciferase expressing cells, a pBabe-Luciferase retroviral vector 
(a gift from J. Downward) was packaged in Phoenix-Ampho cells and used to 
infect HCT116 p53+/+ and p53-/- cells. After selection, cells were transduced 
with lentiviral vectors and selected as in Generation of doxycycline-inducible 
shRNA cell lines section. 1x106 cells were subcutaneously injected into the 
dorsal flank of male nude mice (ICRF nude). Animals were randomly assigned 
to two cohorts. For induction of shRNA expression, one animal cohort 
received doxycycline (Doxycycline diet, 0.2 g/kg food pellet, Harlan D.98186) 
starting 1 day after implantation, and tumour growth was followed over 21 
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days. HCT116lucp53+/+shCrtl (n=6), HCT116lucp53+/+shCtrl DOX (n=6), 
HCT116lucp53+/+shB4#68 (n=5), HCT116lucp53+/+shB4#68 DOX (n=4), 
HCT116lucp53-/-shCtrl (n=5), HCT116lucp53-/-shCtrl DOX (n=6), HCT116lucp53-
/-shB4#68 (n=4), HCT116lucshB4#68 DOX (n=6), HCT116lucp53+/+shB4#64 
(n=6), HCT116lucp53+/+shB4#64 DOX (n=5), HCT116lucp53-/-shB4#68 (n=5), 
HCT116lucshB4#68 DOX (n=5). Mice were anaesthetised, intraperitoneally 
injected with Luciferin (Promega) and imaged using an IVIS Spectrum imaging 
system. Investigators were blinded to group allocation. Images were analysed 
using the IVIS Living Image software. Criteria for the exclusion of animal from 
the analysis were pre-defined based on morbidity unrelated to experimental 
treatment. This was not observed during the experiment and no animals were 
excluded. All animal experiments were performed according to UK Home 
Office guidelines. 
 
Histology 
4ȝm thick tissue sections were mounted, dewaxed, and rehydrated. Antigen 
retrieval was performed with citrate buffer (pH 6.0) in a microwave oven for 
30min. Endogenous peroxidase activity was blocked by incubating sections in 
3% (v/v) hydrogen peroxide for 10min. Sections were blocked with 3% (w/v) 
BSA for 30min and incubated with the monoclonal mouse anti-human Ki-67 
antibody (9106, Thermo Scientific), diluted 1:200 over night at 4°C in a 
humidified chamber. Sections were washed in PBS and incubated with 
biotinylated secondary antibody followed by streptavidin-horseradish-
peroxidase assay (Vector Labs, Dako). Reaction was developed using 3,3'-
diaminobenzidine (Cell Signaling). Slides were counterstained with Gilmore 3 
hematoxylin, dehydrated, cleared, and mounted with coverslips. TUNEL 
assay was performed according to the manufacturer’s instructions (In Situ Cell 
Death Detection Kit, Roche no. 11684795910). 
 
RNAseq analysis  
Total RNA from 3 tumours in each treatment group (HCT116lucp53+/+shCtrl, 
HCT116lucp53+/+shB4#68, HCT116lucp53-/-shCtrl and HCT116lucp53-/-shB4#68 
all treated with DOX) was extracted using RNeasy mini columns (Qiagen) with 
on column DNase I digestion. PolyA+ RNA was extracted using the NEBNext 
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Poly(A) mRNA Magnetic Isolation Module (NEB, Ipswich, MA, USA). For 
library preparation, the NEBNext Ultra RNA Library Prep Kit for Illumina (NEB, 
Ipswich, MA, USA) was used. Quantification and quality control was 
performed using the Experion Automated Electrophoresis System (BioRad, 
Hercules, CA, USA). Sequencing was performed using an Illumina 
NextSeq500 System (Illumina, San Diego, CA, USA). 
Fastq files were mapped to the human genome assembly hg19 using TopHat 
v2.0.7 with default parameters and subsequently normalized to the number of 
mapped reads in the smallest sample. Reads per gene were counted using 
the countOverlaps function from the R package (Genomic Ranges). Weakly 
expressed genes were removed (threshold: mean read count over all samples 
<1) and differentially expressed genes were called using EdgeR. GSE 
analyses 40 were performed with signal2noise metric, 1000 permutations and 
the C2 gene set. Pathway analysis of differentially expressed genes 
(logFC0.7, q0.05) was performed using the DAVID tool 14, 15 with default 
settings. 
 
Analysis of patient data and survival analysis 
Lung cancer data were downloaded from the Gene Expression Omnibus 
(GSE12667) and MAS 5.0 processed signals were generated on Affymetrix 
Human Genome U133 Plus 2.0. Normalised data were log2 transformed. A 
Wilcoxon rank sum test was used to assess significant chances in expression 
between p53+/+ and p53-/- groups for probeset detecting the PFKFB4 gene. 
Analysis of survival data from public datasets for breast cancer 16 and non-
small cell lung cancer 24 was performed using PROGene 11. Patients were 
divided based on median PFKFB4 expression and relapse-free survival was 
analysed. Expression data for PFKFB4 in lung adenocarcinoma were 
extracted from public datasets 8. 
 
Statistical analysis 
Graphs were generated using GraphPad Prism 5.0 (GraphPad software). All 
experiments were performed with three biologically independent replicates 
unless stated otherwise. Sample sizes are calculated to allow significance to 
be reached. Statistical significance of magnitude of changes between different 
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conditions was calculated using the parametric two-tailed unpaired Student t-
tests. Statistical significance was defined as a p-value of less than 0.05. P-
values are depicted as follows: *p0.05, **p0.01, ***p0.001 and 
****p0.0001. n.s. = not significant. 
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FIGURE LEGENDS 
Figure 1: Differential expression of PFKFB4 in p53 deficient cells  
a) HCT116 p53+/+ or p53-/- cells were cultured in full medium for 24 hours. 
Expression of PFKFB1, PFKFB2, PFKFB3 and PFKFB4 was determined by 
qPCR and normalised to B2M. Data are presented as mean ± SEM (n=6). 
b) Levels of ME1, ME2 and TIGAR in p53+/+ or p53-/- HCT116 cells. Data are 
presented as mean ± SEM (n=6). 
c) Expression of PFKFB4 protein in HCT116 p53+/+ and p53-/- cells. Vinculin 
was used as loading control. Bar graph shows the mean ± SEM of 3 replicate 
experiments. 
d) MEFs from tpr53fl/fl mice were infected with Adeno-CRE-GFP to excise the 
floxed allele. mRNA from selected cells was analysed for expression of 
Pfkfb4. Data are presented as mean ± SEM (tpr53+/+ n=7 wt, tpr53-/- n=8). 
e) HCT116 p53+/+ cells were transduced with lentiviral vectors expressing 
inducible shRNA targeting p53. Cells were treated with 1µg/ml doxycycline 
(Dox) or solvent for 8 days. Expression of PFKFB4, ME2, TP53 and p21 was 
determined by qPCR. Data are presented as mean ± SEM (n=4). 
f) SKOV3 cells were transduced with a lentiviral vector expressing wild type 
p53 or a control vector. Expression of TP53, PFKFB4 and ME2 was 
determined by qPCR in monoclonal populations. Data are presented as mean 
± SD (n=3). 
g) Expression of PFKFB4 and p53 protein in cells as F. Actin was used as 
loading control. 
 
Figure 2: p53 represses PFKFB4 expression in cancer cells 
a) HCT116 p53+/+ cells were treated with different concentrations of etoposide 
for 24 hours. Expression of PFKFB4, p21 (CDKN1A) and ME2 was 
determined by qPCR. Data are presented as mean ± SEM (n=3). 
b) Regulation of p21, PFKFB4 and ME2 in p53 wild type LOVO colon cancer 
cells after etoposide treatment. Data are presented as mean ± SD (n=3). 
c) Regulation of p21, PFKFB4 and ME2 in p53 wild type MCF7 breast cancer 
cells after etoposide treatment. Data are presented as mean ± SD (n=3). 
d) Overview of the structure of the human PFKFB4 promoter. Sequences 
corresponding to putative p53 response elements are indicated. (B4 site 1: 
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position chr3:48598858-48598880; B4-site 2: position: chr3:48592906-
48592928; GRCh37/hg19). HCT116 cells (p53+/+ and p53-/-) were subjected to 
chromatin immunoprecipitation assays using p53 specific antibodies (TP53 
Ab), isotype-matched controls (IgG) or no antibody (no Ab). Promoter regions 
corresponding to p53-site 1 (left panel) or p53-site2 (right panel) of the 
PFKFB4 promoter were amplified using qPCR. A p53-site in the p21 promoter 
was used as positive control.  
e) HCT116 p53+/+ cells, LOVO and MCF7 cancer cells were treated with 20µM 
etoposide in the presence or absence of 100nM TSA. Expression of p21, 
PFKFB4 and ME2 mRNA was determined by qPCR. HCT p53+/+ cells data are 
presented as mean ± SEM (n=2). LOVO and MCF7 data are presented as 
mean ± SD (n=3). 
 
Figure 3: PFKFB4 is required for viability of p53 deficient cancer cells 
a) HCT116 p53+/+ and p53-/- cells were transduced with lentiviral vectors 
expressing inducible shRNA targeting PFKFB4 (shPFKFB4 #68 or #64). Cells 
were seeded at low density, treated with 1µg/ml doxycycline (Dox) or solvent 
for 8 days and stained with crystal violet. Left: representative images. Right: 
Quantification. Data are presented as mean ± SEM (n=5) and are relative to 
HCT116 p53+/+ shCtrl cells treated with solvent. 
b) Cells were treated with 1µg/ml doxycycline (Dox) or solvent for 6 days and 
expression of PFKFB4 was determined by qPCR and normalised to B2M. 
Data are presented as mean ± SEM (n=5) and are relative to HCT116 p53+/+ 
shPFKFB4 cells treated with solvent. 
c) HCT116 cells (p53+/+ and p53-/-) expressing inducible shRNAs targeting 
PFKFB4 were stably transfected with pBabe-vectors expressing shRNA-
insensitive versions of PFKFB4 (PFKFB4ins). Cells were seeded al low density 
and treated with doxycycline (Dox) for 8 days. Cultures were fixed and 
analysed by crystal violet staining. Data are presented as mean ± SEM (n=6).  
d) Expression of PFKFB4 in p53 wild type cells (RKO, LOVO, LS174T) or p53 
mutant cells (SW480 and SW620) was determined by qPCR relative to B2M. 
Box plot represents the differential expression of PFKFB4 between both 
groups of cell lines. 
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e) LOVO, LS174Tm SW480 and SW460 cells were transduced with lentiviral 
vectors expressing inducible shRNA targeting PFKFB4 (shPFKFB4 #68 or 
#64). Silencing of PFKFB4 was confirmed by qPCR. 
f) Cells in E were seeded at low density, treated with 1µg/ml doxycycline 
(Dox) or solvent for 8 days and stained with crystal violet. Data are presented 
as mean ± SEM (n=3) and are relative to cells treated with solvent. 
 
Figure 4: PFKFB4 maintains balance between glycolysis and pentose 
phosphate pathway in p53 deficient cancer cells 
a) Downregulation of PFKFB4 protein in HCT116 p53+/+ and p53-/- cells after 6 
days of shRNA-mediated silencing. Actin was used as loading control. 
b) HCT116 p53+/+ and p53-/- cells expressing inducible shRNAs targeting 
PFKFB4 were treated with 1µg/ml doxycycline (Dox) or solvent for 6 days. 
Intracellular levels of fructose 2,6-biphosphate (Fru-2,6-BP) were determined. 
Data are presented as mean ± SEM (n=5). 
c) Extracellular acidification rates (ECAR) and oxygen consumption rates 
(OCR) were determined in cells treated as in A. Graph displays ECAR/OCR 
and data are presented as mean ± SEM. 
d) Changes in ECAR and OCR in HCT116 p53+/+ and p53-/- cells after 
silencing of PFKFB4. Data are presented as mean ± SEM (n=5). 
e) HCT116 p53+/+ and p53-/- cells were treated with doxycycline (Dox) for 6 
days and the labelled with either 14C1 or 14C6 glucose. Relative production of 
CO2 from both substrates was determined. Data are presented as mean ± 
SEM (n=4). 
 
Figure 5: PFKFB4 maintains NADPH production for biosynthetic activity 
and antioxidant production in p53 deficient cancer cells 
a) HCT116 p53+/+ and p53-/- cells expressing inducible shRNAs targeting 
PFKFB4 were treated with 1µg/ml doxycycline (Dox) or solvent for 6 days. 
Levels of NADP+ and NADPH were determined and normalised to total 
protein content. Values are presented relative to solvent controls. Data are 
presented as mean ± SEM (n=8). 
b) Rates of acetate-dependent lipid biosynthesis in HCT116 p53+/+ and p53-/- 
cells. Data are presented as mean ± SEM (n=6). 
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c) HCT116 p53+/+ and p53-/- cells were transfected with 0.25 µg pRL-TK and 
2.5 µg pGL3-SYNwt-luc (SYN-wt) or pGL3-SYNmutSRE1 (SYN-mutSRE1). 
Firefly luciferase activity was determined 48 hours post-transfection and 
normalised to renilla luciferase. Data are presented as mean ± SD (n=3). 
d) Rates of acetate-dependent lipid biosynthesis in HCT116 p53+/+ and p53-/- 
cells after 6 days of PFKFB4 silencing. Data are presented as mean ± SD 
(n=3). 
e) HCT116 (p53+/+ and p53-/-) cells expressing shRNAs targeting PFKFB4 or 
controls were treated with 1µg/ml doxycycline (Dox) for 6 days. ROS levels 
were determined by DCFDA fluorescence. Data are presented as mean ± 
SEM (n=3). 
f) HCT116 p53-/- cells were depleted of PFKFB4 as in E. Cells were treated 
with 10mM N-acetyl cysteine (NAC) 24 hours prior to detection of ROS (n=5). 
g) Diagram of allosteric regulation of glycolytic flux and pentose phosphate 
pathway (PPP) activity by PFKFB4.  
 
Figure 6: PFKFB4 supports tumour growth in p53 deficient cancer cells  
a) HCT116luc p53+/+ and p53-/- cells expressing inducible shRNAs targeting 
PFKFB4 (shPFKB4#68 above and shPFKFB4 #64 below) were injected 
subcutaneously into nude mice. Mice were divided into two cohorts with equal 
tumour burden and one cohort received doxycycline in their food (DOX) 
started one day after implantation. Tumour growth was monitored by in vivo 
quantification of luciferase. Graphs show mean bioluminescence 
(p/sec/cm2/sr) ± SEM for each group. 
b) Representative mice for each group at day 21 are shown. 
c) Analysis of fragmented DNA in apoptotic cells using TUNEL assays in 
tumours recovered at day 21, representative images.  
d) Analysis of proliferation using histological staining for the Ki67 marker 
in tumours recovered at day 21, representative images.  
e) Selected gene sets showing decreased expression in tumours depleted of 
PFKFB4 compared to controls by gene set enrichment analysis (GSEA). 
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